Loss of MSH2 protein expression is a risk factor in early stage cervical cancer

Journal of Clinical Pathology

Volumn 60, Issue 7, 2007, Pages 824-830

  Nijhuis, E R ^a   Nijman, H W ^a   Oien, K A ^b   Bell, A ^c   Ten Hoor, K A ^a   Reesink Peters, N ^a   Boezen, H M ^a   Hollema, H ^a   Van Der Zee, A G J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PARAFFIN; PROTEIN MSH2;

ACCURACY; ADULT; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; EARLY CANCER; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; GENE EXPRESSION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MISMATCH REPAIR; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; UTERINE CERVIX CANCER;

ADULT; FEMALE; HUMANS; LYMPHATIC METASTASIS; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROTEIN ARRAY ANALYSIS; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 34447332812     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.036038     Document Type: Article

References (42)

1. Benedet JL, Odicino F, Maisonneuve P, et al. Carcinoma of the cervix uteri. J Epidemiol Biostat 2001;6:7-43.
2. Creasman WT, Kohler MF. Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? Gynecol Oncol 2004;92:525-9.
3. Ho CM, Chien TY, Huang SH, et al. Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy. Gynecol Oncol 2004;93:458-64.
4. Rutledge TL, Kamelle SA, Tillmanns TD, et al. A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol 2004;95:70-6.
5. Birner P, Schindl M, Obermair A, et al. Overexpression of hypoxia-inducible factor 1-alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693-6.
6. Duk JM, Groenier KH, de Bruijn HW, et al. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol 1996;14:111-18.
7. Ferrandina G, Lauriola L, Distefano MG, et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 2002;20:973-81.
8. van de PG, Holm R, Lie AK, et al. Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis. Gynecol Oncol 2003;89:140-7.
9. Chen Y, Wana J, Fraig MM, et al. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer. Int J Oncol 2003;22:1033-43.
10. Geisler JP, Geisler HE, Miller GA, et al. Immunohistochemical staining of the mismatch repair gene, hMSH2, and survival in patients with ovarian carcinoma. Eur J Gynaecol Oncol 2000;21:237-40.
11. Hardisson O, Moreno-Bueno G, Sanchez L, et al. Tissue microarray immunohistochemical expression analysis of mismatch repair (hMLH1 and hMSH2 genes) in endometrial carcinoma and atypical endometrial hyperplasia: relationship with microsatellite instability. Mod Pathol 2003;16:1148-58.
12. Kohya N, Miyazaki K, Matsukura S, et al. Deficient expression of O(6)-methylguanine-DNA methyl transferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma. Ann Surg Oncol 2002;9:371-9.
13. Leach FS, Polyak K, Burrell M, et al. Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues. Cancer Res 1996;56:235-40.
14. Taubert HW, Bartel F, Kappler M, et al. Reduced expression of hMSH2 protein is correlated to poor survival for soft tissue sarcoma patients. Cancer 2003;97:2273-8.
15. Velasco A, Hewitt SM, Albert PS, et al. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer 2002;94:690-9.
16. Boland CR, Goel A. The silence of the genes: matching mismatch repair defects with tumors. Cancer 2003;98:2091-4.
17. Peltomaki P, Lothe RA, Aaltonen LA, et al. Microsatellite instability is associated with tumors that characterize the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer Res 1993;53:5853-5.
18. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77.
19. Parc Y, Gueroult S, Mourra N, et al. Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut 2004;53:371-5.
20. Chung TK, Cheung TH, Wang VW, et al. Microsatellite instability, expression of hMSH2 and hMLH1 and HPV infection in cervical cancer and their clinico-pathological association. Gynecol Obstet Invest 2001;52:98-103.
21. Chung TK, Ip TY, Hampton GM, et al. Microsatellite instability in cervical carcinoma. Eur J Obstet Gynecol Reprod Biol 2001;94:121-4.
22. Helland A, Borresen-Dale AL, Peltomaki P, et al. Microsatellite instability in cervical and endometrial carcinomas. Int J Cancer 1997;70:499-501.
23. Nishimura M, Furumoto H, Kato T, et al. Microsatellite instability is a late event in the carcinogenesis of uterine cervical cancer. Gynecol Oncol 2000;79:201-6.
24. Ou CY, Chang JG, Tseng HH, et al. Analysis of microsatellite instability in cervical cancer. Int J Gynecol Cancer 1999;9:67-71.
25. Wong YF, Cheung TH, Poon KY, et al. The role of microsatellite instability in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. Gynecol Oncol 2003;89:434-9.
26. Giarnieri E, Mancini R, Pisani T, et al. Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix. Clin Cancer Res 2000;6:3600-6.
27. Ciavattini A, Piccioni M, Tranquilli AL, et al. Immunohistochemical expression of DNA mismatch repair (MMR) system proteins (hMLH1, hMSH2) in cervical preinvasive and invasive lesions. Pathol Res Pract 2005;201:21-5.
28. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000;80:1943-9.
29. Gulmann C, Butler D, Kay E, et al. Biopsy of a biopsy: validation of immunoprofiling in gastric cancer biopsy tissue microarrays. Histopathology 2003;42:70-6.
30. Hendriks Y, Franken P, Dierssen JW, et al. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol 2003;162:469-77.
31. Kallioniemi OP, Wagner U, Kononen J, et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001;10:657-62.
32. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
33. Finan MA, DeCesare S, Fiorica JV, et al. Radical hysterectomy for stage IB1 vs IB2 carcinoma of the cervix: does the new staging system predict morbidity and survival? Gynecol Oncol 1996;62:139- 47.
34. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
35. Berends MJ, Hollema H, Wu Y, et al. MLH1 and MSH2 protein expression as a pre-screening marker in hereditary and non-hereditary endometrial hyperplasia and cancer. Int J Cancer 2001;92:398-403.
36. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
37. Ho CM, Chien TY, Huang SH, et al. Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy. Gynecol Oncol 2004;93:458-64.
38. Jascur T, Boland CR. Structure and function of the components of the human DNA mismatch repair system. Int J Cancer 2006;119:2030- 5.
39. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
40. Wisman GB, Nijhuis ER, Hoque MO, et al. Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer 2006;119:1908-14.
41. Feng Q, Balasubramanian A, Hawes SE, et al. Detection of hypermethylated genes in women with and without cervical neoplasia. J Natl Cancer Inst 2005;97:273-82.
42. Virmani AK, Muller C, Rathi A, et al. Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 2001;7:584-9.